Literature DB >> 1434517

Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency.

C A Stanley1, F Sunaryo, D E Hale, J P Bonnefont, F Demaugre, J M Saudubray.   

Abstract

In a boy with a defect in fatty acid oxidation due to the hepatic form of carnitine palmitoyltransferase-1 deficiency, plasma carnitine concentrations were found to be twice normal. The elevation in plasma carnitine levels was accompanied by an unusually high renal threshold for free carnitine, suggesting a secondary increase in carnitine transport. Similar to other fatty acid oxidation disorders involving the carnitine cycle, urinary dicarboxylic acids were not abnormally elevated during illnesses. The combination of elevated plasma carnitine levels and absence of dicarboxylic aciduria may help to distinguish the hepatic form of carnitine palmitoyltransferase-1 deficiency from other defects in fatty acid oxidation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1434517     DOI: 10.1007/bf01800021

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  10 in total

1.  Specificity and characteristics of the carnitine transport in human heart cells (CCL 27) in culture.

Authors:  P Molstad; T Bohmer; K Eiklid
Journal:  Biochim Biophys Acta       Date:  1977-12-01

2.  Deficiency of carnitine palmitoyltransferase I.

Authors:  J P Bonnefont; R Haas; J Wolff; L P Thuy; R Buchta; J E Carroll; J M Saudubray; F Demaugre; W L Nyhan
Journal:  J Child Neurol       Date:  1989-07       Impact factor: 1.987

3.  Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts.

Authors:  W R Treem; C A Stanley; D N Finegold; D E Hale; P M Coates
Journal:  N Engl J Med       Date:  1988-11-17       Impact factor: 91.245

4.  Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency.

Authors:  P F Bougnères; J M Saudubray; C Marsac; O Bernard; M Odièvre; J Girard
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

Review 5.  New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency.

Authors:  C A Stanley
Journal:  Adv Pediatr       Date:  1987

6.  Primary systemic carnitine deficiency. II. Renal handling of carnitine.

Authors:  A G Engel; C J Rebouche; D M Wilson; A M Glasgow; C A Romshe; R P Cruse
Journal:  Neurology       Date:  1981-07       Impact factor: 9.910

7.  Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels.

Authors:  C A Stanley; D E Hale; P M Coates; C L Hall; B E Corkey; W Yang; R I Kelley; E L Gonzales; J R Williamson; L Baker
Journal:  Pediatr Res       Date:  1983-11       Impact factor: 3.756

Review 8.  Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake.

Authors:  C A Stanley; S DeLeeuw; P M Coates; C Vianey-Liaud; P Divry; J P Bonnefont; J M Saudubray; M Haymond; F K Trefz; G N Breningstall
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

9.  Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities.

Authors:  F Demaugre; J P Bonnefont; G Mitchell; N Nguyen-Hoang; A Pelet; M Rimoldi; S Di Donato; J M Saudubray
Journal:  Pediatr Res       Date:  1988-09       Impact factor: 3.756

10.  Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies.

Authors:  F Demaugre; J P Bonnefont; M Colonna; C Cepanec; J P Leroux; J M Saudubray
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

  10 in total
  10 in total

1.  Lethal neonatal presentation of carnitine palmitoyltransferase I deficiency.

Authors:  F Invernizzi; A B Burlina; A Donadio; G Giordano; F Taroni; B Garavaglia
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

2.  Evaluation of diagnostic fasting in the investigation of hypoglycemia in children omani experienc.

Authors:  Bhasker Bappal; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2007-10

Review 3.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

4.  Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation.

Authors:  J M Stoler; M A Sabry; C Hanley; C L Hoppel; V E Shih
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 5.  Defects in activation and transport of fatty acids.

Authors:  M Brivet; A Boutron; A Slama; C Costa; L Thuillier; F Demaugre; D Rabier; J M Saudubray; J P Bonnefont
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

6.  Carnitine palmitoyltransferase I deficiency in neonate identified by dried blood spot free carnitine and acylcarnitine profile.

Authors:  K G Sim; V Wiley; K Carpenter; B Wilcken
Journal:  J Inherit Metab Dis       Date:  2001-02       Impact factor: 4.982

7.  Association of Abnormal Serum L-Carnitine Levels with Idiopathic Changes in Left Ventricular Geometry in Pediatric and Adolescent Patients.

Authors:  Mohsen Shahidi; Khaled Rahmani; Abdorrahim Afkhamzadeh
Journal:  Iran J Med Sci       Date:  2022-05

8.  Reliable Diagnosis of Carnitine Palmitoyltransferase Type IA Deficiency by Analysis of Plasma Acylcarnitine Profiles.

Authors:  M Rebecca Heiner-Fokkema; Frédéric M Vaz; Ronald Maatman; Leo A J Kluijtmans; Francjan J van Spronsen; Dirk-Jan Reijngoud
Journal:  JIMD Rep       Date:  2016-06-14

Review 9.  Disorders of mitochondrial long-chain fatty acid oxidation.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 10.  Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.

Authors:  Suzan J G Knottnerus; Jeannette C Bleeker; Rob C I Wüst; Sacha Ferdinandusse; Lodewijk IJlst; Frits A Wijburg; Ronald J A Wanders; Gepke Visser; Riekelt H Houtkooper
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.